Metformin Ameliorates A<i>β</i> Pathology by Insulin-Degrading Enzyme in a Transgenic Mouse Model of Alzheimer’s Disease

Lu, Xin-Yi; Huang, Shun; Chen, Qu-Bo; Zhang, Dapeng; Li, Wanyan; Ao, Ran; Leung, Feona Chung-Yin; Zhang, Zhimin; Huang, Jisheng; Tang, Ying; Zhang, Shi-Jie

doi:https://doi.org/10.1155/2020/2315106

Oxidative Medicine and Cellular Longevity

On this page

Abstract Introduction Methods Results Discussion Data Availability Conflicts of Interest Authors’ Contributions Acknowledgments References Copyright Related Articles

Special Issue

Pharmaceutical and Pharmacological Aspects of Modulation of Oxidative Stress 2020

View this Special Issue

Research Article | Open Access

Volume 2020 | Article ID 2315106 | https://doi.org/10.1155/2020/2315106

Metformin Ameliorates Aβ Pathology by Insulin-Degrading Enzyme in a Transgenic Mouse Model of Alzheimer’s Disease

Xin-Yi Lu,^1,2Shun Huang,³Qu-Bo Chen,¹Dapeng Zhang,⁴Wanyan Li,⁴Ran Ao,⁴Feona Chung-Yin Leung,⁵Zhimin Zhang,⁴Jisheng Huang,^6,7,8Ying Tang ,⁹and Shi-Jie Zhang²

Academic Editor: Luciano Saso

Received29 Jan 2020

Revised05 Mar 2020

Accepted25 Mar 2020

Published21 Apr 2020

Abstract

Alzheimer’s disease (AD) is the most common neurodegenerative disease. The accumulation of amyloid beta (Aβ) is the main pathology of AD. Metformin, a well-known antidiabetic drug, has been reported to have AD-protective effect. However, the mechanism is still unclear. In this study, we tried to figure out whether metformin could activate insulin-degrading enzyme (IDE) to ameliorate Aβ-induced pathology. Morris water maze and Y-maze results indicated that metformin could improve the learning and memory ability in APP^swe/PS1^dE9 (APP/PS1) transgenic mice. ¹⁸F-FDG PET-CT result showed that metformin could ameliorate the neural dysfunction in APP/PS1 transgenic mice. PCR analysis showed that metformin could effectively improve the mRNA expression level of nerve and synapse-related genes (Syp, Ngf, and Bdnf) in the brain. Metformin decreased oxidative stress (malondialdehyde and superoxide dismutase) and neuroinflammation (IL-1β and IL-6) in APP/PS1 mice. In addition, metformin obviously reduced the Aβ level in the brain of APP/PS1 mice. Metformin did not affect the enzyme activities and mRNA expression levels of Aβ-related secretases (ADAM10, BACE1, and PS1). Meanwhile, metformin also did not affect the mRNA expression levels of Aβ-related transporters (LRP1 and RAGE). Metformin increased the protein levels of p-AMPK and IDE in the brain of APP/PS1 mice, which might be the key mechanism of metformin on AD. In conclusion, the well-known antidiabetic drug, metformin, could be a promising drug for AD treatment.

1. Introduction

Alzheimer’s disease (AD), a progressive neurodegenerative disease with a high incidence rate in this century, has cognitive and functional ability decline with the disease progress. AD is mainly characterized by the accumulation of amyloid beta (Aβ) plaques and neurofibrillary tangles (NFTs) in the brain [1–3]. Accumulation of Aβ, which is generated from the amyloid precursor protein (APP), is the main hallmark of AD [4]. Thus, targeting Aβ is leading to a potential therapeutic strategy [5]. However, a series of clinical trials, such as inhibitors of β-secretase (BACE1) or γ-secretase (PS1), have failed [6, 7]. Promoting the degradation or clearance of Aβ is considered as an alternative therapeutic strategy [8].

Diabetes mellitus (DM) is also associated with a higher risk of AD [9, 10], in which insulin deficiency or insulin resistance may be responsible. Metformin, as a major antidiabetic drug, has been demonstrated to reduce β-secretase activity, promote phospho-thr-231-tau degradation, and influence mitochondrial function [10–14]. Recently, some molecules, which are widely studied in diabetes, have been proved to affect Aβ clearance, including insulin-degrading enzyme (IDE), neprilysin (NEP), receptor for advanced glycation end products (RAGE), and matrix metalloproteinases (MMPs) [15–19]. Among these molecules, IDE plays an important role in both diabetes and AD. Loss-of-function mutation in the IDE gene can lead to impaired degradation of Aβ [20]. Colocalization and codeposition of IDE with Aβ plaques can be found in the AD brain. Inhibition of IDE in the brain is identified as one of the major factors involved in the crosstalk between DM and AD [21]. However, whether metformin could protect against AD through the IDE pathway is still unknown.

APP^swe/PS1^dE9 (APP/PS1) double transgenic mice were used for the study. The APP/PS1 mouse exhibits the Aβ plaque formation and memory impairment, which is similar to clinical phenotype [22], including memory deficits, anxiety, hyperactivity, and social interaction impairment. Metformin, an experimental therapy, was used to explore the hypothesis that metformin protects against AD via IDE signaling in APP/PS1 mice.

2. Material and Methods

2.1. Materials

Metformin and Thioflavin T (ThT) reagent were purchased from Sigma-Aldrich (Saint Louis, MO, USA). A BCA protein assay kit and superoxide dismutase (SOD) assay kit were obtained from Beyotime Biotechnology. The malondialdehyde (MDA) Assay Kit (TBA method) was purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). qPCR reagents and ECL kit were purchased from Invitrogen. All the antibodies were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA).

2.2. Animals and Treatments

The 7-month-old male APP/PS1 double transgenic mice and wild-type mice (C57BL/6) were obtained from the Model Animal Research Institute of Nanjing University (Nanjing, China) and maintained at the laboratory animal center of Guangzhou Medical University under the standard housing conditions with free access to food and water. The animal management was approved by the Institutional Animal Care and Use Committee of Guangzhou Medical University (SCXK2019-0013). All mice were randomly divided into three groups: wild type (WT, ), APP/PS1 (), and APP/PS1+metformin (200 mg/kg/day, ) [23, 24]. After oral drug administration for 8 weeks, mice were performed behavioral tests and subsequently sacrificed for the collection of brains.

2.3. Morris Water Maze Test

The Morris water maze test was performed to evaluate the spatial memory performance. The opaque platform with a diameter of 10 cm was positioned 1 cm beneath the water surface. The duration of training and testing session was 60 s. In the training session, mice completed four trials daily with at least 20 minutes of interval between two trials for six consecutive days. Each mouse was released into the water by facing the wall in one of the four quadrants. If the mouse failed to reach the platform within 60 s, it would be directed to the platform and stay there for 15 s. In the testing session, the platform was removed from the pool and the mice were allowed to search for the platform for 60 s. A computerized video imaging analysis system (Feidi, Guangzhou) was used to record and analyze the swimming paths in the maze.

2.4. Y-Maze Test

The Y-maze test was performed to evaluate the working memory performance. The apparatus consisted of three arms (one start arm and two goal arms) of cm connected by an intersection. The duration of training and testing session was 2 min. Before the training and testing sessions, the body weight of mice would reduce to 90% by food restriction. In the training session, mice completed 10 trials daily with at least 20 min interval between two trials for four consecutive days. Prior to the reward alternation testing session, each mouse would consume the food which was filled at the end of the arm for 4-6 times to habituate to the maze. The choice for each goal arm should be given equally, and the percentage of correct choices would be calculated to analysis.

2.5. ¹⁸F-FDG PET Imaging

After 8 weeks of metformin administration, the microPET-CT was used to evaluate brain glucose uptake. ¹⁸F-Fluordeoxyglucose (¹⁸F-FDG) was intraperitoneally injected into animals. The mice were scanned by using a Focus 220 microPET scanner (Siemens Medical Solutions USA, Inc., Knoxville, TN, USA). Dynamic scans were conducted for 1 h. PET images were reconstructed using the microPET-CT manager (Siemens Medical Solutions USA, Inc.). To evaluate relative glucose metabolism, the ratio of the SUV standardized uptake value was obtained by dividing the SUV of each region with the SUV of the whole brain.

2.6. ELISA

Brain tissues were homogenized with saline, containing a cocktail of protease inhibitors. Samples were centrifuged by for 15 min. The supernatants were measured for IL-1β, IL-6 (Thermo Fisher Scientific), Aβ1-40, Aβ1-42 (Invitrogen), and α-, β-, and γ-secretases (R&D Systems, USA) by using the ELISA kits according to the manufacturer’s proposals.

2.7. ThT Staining

The sections were washed three times in PBS at room temperature and then incubated with a ThT reagent (50 μM) for 30 min. After washing three times in PBS, the sections were captured by a fluorescence microscope (Leica).

2.8. Measurement of SOD and MDA

The brain tissues were homogenized and centrifuged by for 15 min. The supernatants were used to test SOD activity and MDA level according to the kit instructions (Nanjing Jiancheng Bioengineering Institute).

2.9. qPCR

Total RNA from brain tissues were extracted using a TRIzol reagent. Reverse transcription was treated with an ExScript RT Reagent Kit (Invitrogen). Real-time PCR analysis was undertaken using SYBR Premix Ex Taq (Invitrogen). The transcriptions were investigated for several target genes, including synaptophysin (Syp): For 5-GTGCTGCAATGGGTCTTCG-3 and Rev 5-CCGTGGCCAGAAAGTCCAG-3; nerve growth factor (Ngf): For 5-CAAGGACGCAGCTTTCTATACTG-3 and Rev 5-CTTCAGGGACAGAGTCTCCTTCT-3; brain-derived neurotrophic factor (Bdnf): For 5-TACTTCGGTTGCATGAAGGCG-3 and Rev 5-GTCAGACCTCTCGAACCTGCC-3; a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10): For 5-TTCTCCCTCCGGATCGATGT-3 and Rev 5-ATACTGACCTCCCATCCCCG-3; beta-secretase 1 (BACE1): For 5-ACTTTACACTCTGTTCTGGGTGG-3 and Rev 5-ACCACAAAGCCTGGCAATCTC-3; presenilin 1 (PS1): For 5-AATGACGACAACGGTGAGGG-3 and Rev 5-CCAGATTAGGTGCTTCCCCG-3; low-density lipoprotein receptor-related protein 1 (LRP1): For 5-GGACCACCATCGTGGAAA-3 and Rev 5-TCCCAGCCACGGTGATAG-3; receptor for advanced glycation end products (RAGE): For 5-GGACCCTTAGCTGGCACTTAGA-3 and Rev 5-GAGTCCCGTCTCAGGGTGTCT-3; and β-actin: For 5-AGAGCTACGAGCTGCCTGAC-3 and Rev 5-AGCACTGTGTTGGCGTACAG-3.

2.10. Western Blotting

The fresh brain tissues were homogenated with RIPA buffer containing 1% phenylmethanesulfonyl fluoride and phosphatase inhibitors. The samples was separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto PVDF membranes. The blotting membranes were blocked with 5% BSA. The membranes were incubated at 4°C overnight with the following primary antibodies: anti-p-AMP-activated protein kinase (AMPK), anti-AMPK, anti-IDE, anti-NEP, and anti-β-actin. All the antibodies were purchased from CST. The membranes were incubated with a secondary antibody at room temperature. The membranes were covered with mixed liquid from the ECL Chemiluminescent Substrate Reagent Kit. The bands were scanned by a luminescent image analyzer (Invitrogen).

2.11. Statistical Analysis

All statistical analyses were conducted by SPSS 20.0 software. One-way analysis of variance (ANOVA) and Student -test were used to analyze. Data were expressed as . was considered significant.

3. Results

3.1. Metformin Ameliorates Learning and Memory Dysfunctions in APP/PS1 Mice

To prove the therapeutic effect of metformin on APP/PS1 mice, the Morris water maze and Y-maze tests were used to assess the cognitive function. Results showed that APP/PS1 mice suffered an obvious decline in cognitive function. Metformin could significantly improve escape latency, increase the crossing times, and shorten the time of finding the platform (Figures 1(a)–1(c)). Swimming speed differences among the three groups did not have any statistical significance (Figure 1(d)). In the Y-maze test, APP/PS1 mice showed a significant downward trend in spontaneous alternation, compared to the WT group. After metformin treatment, the mice exhibited better performance than the APP/PS1 group (Figure 1(e)).

(a)

(b)

(c)

(d)

(e)

3.2. Metformin Improves Brain Function in APP/PS1 Mice

Decreased glucose metabolism is the characteristic symptom of AD. ¹⁸F-FDG-PET was used to evaluate the cerebral metabolism. As shown in Figure 2, microPET-CT imaging suggested that ¹⁸F-FDG uptake intensity was sharply decreased in the brain of APP/PS1 mice. Metformin remarkably increased ¹⁸F-FDG uptake in the brain of APP/PS1 mice. In addition, the mRNA expression levels of neurotrophic factors (Bdnf and Ngf) and synaptic factor (Syp) were significantly reduced in APP/PS1 mice (Figures 3(a)–3(c)). Metformin significantly improved the mRNA expression levels of neurotrophic factors and synapse-related proteins.

(a)

(b)

(a)

(b)

(c)

3.3. Metformin Reduces Oxidative Stress and Inflammation in the Brain of APP/PS1 Mice

Neural oxidative stress and inflammation are the key pathologies of AD [25]. In the brain of APP/PS1 mice, the level of MDA was increased, and the activity of SOD was reduced (Figures 4(a) and 4(b)). Metformin significantly relieved the oxidative stress status. In addition, the levels of inflammatory markers, IL-1β and IL-6, were significantly increased in the brain of APP/PS1 mice (Figures 4(c) and 4(d)). Metformin reduced the levels of IL-1β and IL-6. These data suggested that metformin could inhibit oxidative stress and inflammation in APP/PS1 mice.

(a)

(b)

(c)

(d)

3.4. Metformin Reduces Aβ Accumulation in the Brain of APP/PS1 Mice

The accumulation of Aβ is the main pathological feature of AD. The brain of APP/PS1 mice is overloaded with Aβ. Thus, Aβ levels were further studied. ELISA results indicated that metformin effectively reduced the levels of Aβ1-40 and Aβ1-42 in the brain of APP/PS1 mice (Figures 5(a) and 5(b)). ThT staining results further confirmed that metformin ameliorated Aβ accumulation in the brain of APP/PS1 mice (Figure 5(c)). These were strong evidences that metformin could reduce Aβ accumulation in APP/PS1 mice.

(a)

(b)

(c)

3.5. Metformin Activates AMPK and Increases IDE in the Brain of APP/PS1 Mice

We next studied how metformin influences Aβ metabolism. Sequential cleavage of the APP by β- and γ-secretases can produce Aβ [26]. Thus, we firstly detected these secretases. ELISA results showed that metformin had no effect on α-, β-, or γ-secretase (Figures 6(a)–6(c)). The mRNA expression levels of ADAM10, BACE1, and PS1 were also tested. Metformin did not affect these gene expression levels except for a slight decrease of BACE1 (Figures 6(d)–6(f)). We next detected the Aβ transportation-related gene. Results showed that metformin also had no effect on the mRNA expression levels of LRP1 and RAGE (Figures 6(g) and 6(h)). In addition, IDE and NEP, as the degrading enzymes of Aβ, are other key aspects of the process of Aβ clearance. We assessed the protein expression levels of IDE and NEP in the brain of APP/PS1 mice (Figure 7). The IDE and NEP expression levels were significantly decreased in APP/PS1 mice compared to wild-type mice. Metformin significantly increased the expression level of IDE, but not NEP, in the APP/PS1 mice. Previous studies have reported that the AMPK pathway is involved in metformin effect [24, 27–30]. Our results verified this phenomenon. Metformin significantly increased the protein expression level of p-AMPK. These data suggested that the IDE signaling pathway might participate in the neuroprotective effect of metformin.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(a)

(b)

(c)

(d)

4. Discussion

In this study, we verified that the antidiabetic drug, metformin, could effectively ameliorate AD symptom in APP/PS1 double transgenic mice. After 8 weeks’ treatment, we found that metformin could relieve learning and memory dysfunction and improve brain function. Meanwhile, metformin signally inhibited oxidative stress and neuroinflammation. Furthermore, metformin activates AMPK and increases IDE in the brain of APP/PS1 mice, which might be the key neuroprotective mechanism of metformin.

Aβ accumulation is the main pathology of AD, which can cause the cascade reaction and induce neural apoptosis [31]. Studies have shown that metformin is beneficial for AD patients [10–12]. In this experiment, we further investigated the neuroprotective mechanism of metformin on APP/PS1 mice. We did the preliminary experiments: different dosages of metformin (25, 50, 100, and 200 mg/kg/day) were given to APP/PS1 mice. Morris water maze test results indicated that metformin (200 mg/kg/day) was the best dosage (data not shown), which was consistent with previous studies [23, 24]. Behavioral studies (Morris water maze and Y-maze) confirmed that metformin could significantly improve learning and memory in APP/PS1 mice, which was consistent with previous studies. In addition, metformin improved cerebral metabolism and brain function and reduced the level of Aβ.

Aβ accumulation exacerbates oxidative damage and inflammation. Aβ can increase the synthesis of the superoxide anion, reduce the activity of catalase and SOD, activate MDA production, and finally produce reactive oxygen species [30]. In our findings, we found that the contents of MDA were significantly increased and SOD activity was significantly decreased in APP/PS1 mice. After metformin treatment, oxidative stress was relieved. Aβ accumulation can increase the levels of IL-1β and IL-6, the proinflammatory factors, in APP/PS1 mice [32, 33]. Neuroinflammation can also exacerbate AD pathology [25]. In this study, metformin reduced the levels of IL-1β and IL-6 in APP/PS1 mice.

Aβ production is strongly linked with α-, β-, and γ-secretases [26]. When APP is proteolytically processed by β- and γ-secretases, Aβ production is increased. When the activity of α-secretase is increased, Aβ production is inhibited. Aβ transportation is another way of Aβ metabolism. RAGE and LRP1 are the two main molecules, which participate in Aβ transportation [34]. In this study, both ELISA and qPCR results showed that metformin had little influence on α-, β-, and γ-secretases and RAGE and LRP1, except for a small reduction in BACE1 expression, which was consistent with a previous study [11]. These results indicated that except Aβ production and transportation, other signaling pathways might also be involved in the effect of metformin.

AMPK is a crucial factor in the regulation of intracellular systems [30]. AMPK activation can enhance anti-inflammatory effect, which might be regulated by AMPK/mTOR and AMPK/NF-κB signaling pathways [24, 27–30]. Metformin was supposed to have a potential pharmacological effect, due to AMPK activation [35]. In some studies, AMPK/SIRT1 takes part in the nonamyloidogenic pathway to improve AD [36]. In this study, metformin obviously activated AMPK in the brain of APP/PS1 mice. In regard to Aβ clearance, IDE and NEP are the main cellular degrading enzymes of Aβ. Early findings showed that IDE could regulate Aβ and insulin levels in vivo [37]. The major locations of IDE are the cytosol, mitochondria, and peroxisomes [38]. IDE is specific toward β-structure-forming substrates of toxic oligomers (Aβ) [39]. The activity of IDE in the brain decreases with age and during early stages of AD. Overexpression of IDE in transgenic mice can prevent amyloid plaque formation [40]. Inhibition of IDE is identified as one of the crosstalk between T2D and AD [21]. In our findings, the protein expression levels of IDE and NEP were significantly decreased in APP/PS1 mice. Metformin effectively increased the protein level of IDE. These data indicated that the IDE pathway might also participate in the neuroprotective effect of metformin.

In conclusion, we provided the evidence that metformin had beneficial effects by reducing the Aβ level through the IDE pathway in APP/PS1 mice. In addition, metformin could decrease inflammation and oxidative stress. However, further studies are still needed. Metformin might offer a new promising avenue in AD treatment.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Xin-Yi Lu, Shun Huang, and Qu-Bo Chen finished most of the experiments; Dapeng Zhang, Wanyan Li, Ran Ao, Feona Chung-Yin Leung, and Zhimin Zhang helped with data organization. Ying Tang and Shi-Jie Zhang helped to revise the manuscript. Jisheng Huang, Ying Tang, and Shi-Jie Zhang designed the experiments and modified the manuscript. Xin-Yi Lu, Shun Huang, and Qu-Bo Chen contributed equally to this work.

Acknowledgments

This work was supported by the Project of Administration of Traditional Chinese Medicine of Guangdong Province of China (Project No. 20190408212815).

References

D. J. Selkoe and M. B. Podlisny, “Deciphering the genetic basis of Alzheimer's disease,” Annual Review of Genomics and Human Genetics, vol. 3, pp. 67–99, 2002.
View at: Publisher Site | Google Scholar
D. M. Walsh and D. J. Selkoe, “Deciphering the molecular basis of memory failure in Alzheimer's disease,” Neuron, vol. 44, no. 1, pp. 181–193, 2004.
View at: Publisher Site | Google Scholar
Y. Yang and W. Song, “Molecular links between Alzheimer's disease and diabetes mellitus,” Neuroscience, vol. 250, pp. 140–150, 2013.
View at: Publisher Site | Google Scholar
S. Sinha, J. P. Anderson, R. Barbour et al., “Purification and cloning of amyloid precursor protein β-secretase from human brain,” Nature, vol. 402, no. 6761, pp. 537–540, 1999.
View at: Publisher Site | Google Scholar
P. Picone, D. Nuzzo, D. Giacomazza, and M. Di Carlo, “β-Amyloid peptide: the cell compartment multi-faceted interaction in Alzheimer's disease,” Neurotoxicity Research, vol. 37, no. 2, pp. 250–263, 2020.
View at: Publisher Site | Google Scholar
J. Zhang, Y. Guo, Y. Wang, L. Song, R. Zhang, and Y. Du, “Long-term treadmill exercise attenuates Aβ burdens and astrocyte activation in APP/PS1 mouse model of Alzheimer's disease,” Neuroscience Letters, vol. 666, pp. 70–77, 2018.
View at: Publisher Site | Google Scholar
K. Yin, J. Jin, X. Zhu et al., “CART modulates beta-amyloid metabolism-associated enzymes and attenuates memory deficits in APP/PS1 mice,” Neurological Research, vol. 39, no. 10, pp. 885–894, 2017.
View at: Publisher Site | Google Scholar
N. L. Sikanyika, H. C. Parkington, A. I. Smith, and S. Kuruppu, “Powering amyloid beta degrading enzymes: a possible therapy for Alzheimer's disease,” Neurochemical Research, vol. 44, no. 6, pp. 1289–1296, 2019.
View at: Publisher Site | Google Scholar
I. Kazkayasi, M.-A.-M. Ismail, C. Parrado-Fernandez et al., “Lack of insulin results in reduced seladin-1 expression in primary cultured neurons and in cerebral cortex of STZ-induced diabetic rats,” Neuroscience Letters, vol. 633, pp. 174–181, 2016.
View at: Publisher Site | Google Scholar
P. Picone, S. Vilasi, F. Librizzi et al., “Biological and biophysics aspects of metformin-induced effects: cortex mitochondrial dysfunction and promotion of toxic amyloid pre-fibrillar aggregates,” Aging, vol. 8, no. 8, pp. 1718–1734, 2016.
View at: Publisher Site | Google Scholar
Y. Chen, K. Zhou, R. Wang et al., “Antidiabetic drug metformin (Glucophage^R) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 10, pp. 3907–3912, 2009.
View at: Publisher Site | Google Scholar
M. P. Sajan, B. C. Hansen, M. G. Higgs et al., “Atypical PKC, PKCλ/ι, activates β-secretase and increases Aβ_1-40/42 and phospho-tau in mouse brain and isolated neuronal cells, and may link hyperinsulinemia and other aPKC activators to development of pathological and memory abnormalities in Alzheimer's disease,” Neurobiology of Aging, vol. 61, pp. 225–237, 2018.
View at: Publisher Site | Google Scholar
P. Imfeld, M. Bodmer, S. S. Jick, and C. R. Meier, “Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study,” Journal of the American Geriatrics Society, vol. 60, no. 5, pp. 916–921, 2012.
View at: Publisher Site | Google Scholar
P. Picone, D. Nuzzo, L. Caruana et al., “Metformin increases APP expression and processing via oxidative stress, mitochondrial dysfunction and NF-κB activation: use of insulin to attenuate metformin's effect,” Biochimica et Biophysica Acta (BBA) - Molecular Cell ResearchBiochimica et Biophysica Acta, vol. 1853, no. 5, pp. 1046–1059, 2015.
View at: Publisher Site | Google Scholar
J.-M. Paumier, N. A. Py, L. García-González et al., “Proamyloidogenic effects of membrane type 1 matrix metalloproteinase involve MMP-2 and BACE-1 activities, and the modulation of APP trafficking,” The FASEB Journal, vol. 33, no. 2, pp. 2910–2927, 2019.
View at: Publisher Site | Google Scholar
K. J. Yin, J. R. Cirrito, P. Yan et al., “Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-β peptide catabolism,” The Journal of Neuroscience, vol. 26, no. 43, pp. 10939–10948, 2006.
View at: Publisher Site | Google Scholar
P. Yan, X. Hu, H. Song et al., “Matrix metalloproteinase-9 degrades amyloid-β fibrils in vitro and compact plaques in situ,” Journal of Biological Chemistry, vol. 281, no. 34, pp. 24566–24574, 2006.
View at: Publisher Site | Google Scholar
A. Fragkouli, E. C. Tsilibary, and A. K. Tzinia, “Neuroprotective role of MMP-9 overexpression in the brain of Alzheimer's 5xFAD mice,” Neurobiology of Disease, vol. 70, pp. 179–189, 2014.
View at: Publisher Site | Google Scholar
K. Baranger, Y. Marchalant, A. E. Bonnet et al., “MT5-MMP is a new pro-amyloidogenic proteinase that promotes amyloid pathology and cognitive decline in a transgenic mouse model of Alzheimer's disease,” Cellular and Molecular Life Sciences, vol. 73, no. 1, pp. 217–236, 2016.
View at: Publisher Site | Google Scholar
W. Farris, S. Mansourian, M. A. Leissring et al., “Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid β-protein,” The American Journal of Pathology, vol. 164, no. 4, pp. 1425–1434, 2004.
View at: Publisher Site | Google Scholar
M. W. Akhtar, S. Sanz-Blasco, N. Dolatabadi et al., “Elevated glucose and oligomeric β-amyloid disrupt synapses via a common pathway of aberrant protein S -nitrosylation,” Nature Communications, vol. 7, no. 1, article 10242, 2016.
View at: Publisher Site | Google Scholar
H. Huang, S. Nie, M. Cao et al., “Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice,” Age, vol. 38, no. 4, pp. 303–322, 2016.
View at: Publisher Site | Google Scholar
S. A. Farr, E. Roesler, M. L. Niehoff, D. A. Roby, A. McKee, and J. E. Morley, “Metformin improves learning and memory in the SAMP8 mouse model of Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 68, no. 4, pp. 1699–1710, 2019.
View at: Publisher Site | Google Scholar
Z. Ou, X. Kong, X. Sun et al., “Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice,” Brain, Behavior, and Immunity, vol. 69, pp. 351–363, 2018.
View at: Publisher Site | Google Scholar
S. Kyrkanides, R. H. Tallents, J.-n. H. Miller et al., “Osteoarthritis accelerates and exacerbates Alzheimer's disease pathology in mice,” Journal of Neuroinflammation, vol. 8, no. 1, article 112, 2011.
View at: Publisher Site | Google Scholar
F. Song, T. Liu, S. Meng, F. Li, Y. Zhang, and L. Jiang, “Insulin-like growth factor-1 alleviates expression of Aβ_1-40 and α-, β-, and γ-secretases in the cortex and hippocampus of APP/PS1 double transgenic mice,” Journal of Molecular Neuroscience, vol. 66, no. 4, pp. 595–603, 2018.
View at: Publisher Site | Google Scholar
Z. Gong, J. Huang, B. Xu et al., “Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice,” Journal of Neuroinflammation, vol. 16, no. 1, p. 62, 2019.
View at: Publisher Site | Google Scholar
R. Corpas, C. Grinan-Ferre, E. Rodriguez-Farre, M. Pallas, and C. Sanfeliu, “Resveratrol induces brain resilience against Alzheimer neurodegeneration through proteostasis enhancement,” Molecular Neurobiology, vol. 56, no. 2, pp. 1502–1516, 2019.
View at: Publisher Site | Google Scholar
H. Zhang, C. Zhao, G. Cao et al., “Berberine modulates amyloid-β peptide generation by activating AMP-activated protein kinase,” Neuropharmacology, vol. 125, pp. 408–417, 2017.
View at: Publisher Site | Google Scholar
M. Markowicz-Piasecka, J. Sikora, A. Szydlowska, A. Skupien, E. Mikiciuk-Olasik, and K. M. Huttunen, “Metformin - a future therapy for neurodegenerative diseases : theme: drug discovery, development and delivery in Alzheimer's disease guest editor: Davide Brambilla,” Pharmaceutical Research, vol. 34, no. 12, pp. 2614–2627, 2017.
View at: Publisher Site | Google Scholar
Y. M. Li, M. Xu, M. T. Lai et al., “Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1,” Nature, vol. 405, no. 6787, pp. 689–694, 2000.
View at: Publisher Site | Google Scholar
L. Hoeijmakers, S. R. Ruigrok, A. Amelianchik et al., “Early-life stress lastingly alters the neuroinflammatory response to amyloid pathology in an Alzheimer’s disease mouse model,” Brain, Behavior, and Immunity, vol. 63, pp. 160–175, 2017.
View at: Publisher Site | Google Scholar
M. L. de Lemos, A. V. de la Torre, D. Petrov et al., “Evaluation of hypoxia inducible factor expression in inflammatory and neurodegenerative brain models,” The International Journal of Biochemistry & Cell Biology, vol. 45, no. 7, pp. 1377–1388, 2013.
View at: Publisher Site | Google Scholar
Q. Liu, J. Zhang, H. Tran et al., “LRP1 shedding in human brain: roles of ADAM10 and ADAM17,” Molecular Neurodegeneration, vol. 4, no. 1, p. 17, 2009.
View at: Publisher Site | Google Scholar
R. D. Yudhani, I. Astuti, M. Mustofa, D. Indarto, and M. Muthmainah, “Metformin modulates cyclin D1 and P53 expression to inhibit cell proliferation and to induce apoptosis in cervical cancer cell lines,” Asian Pacific Journal of Cancer Prevention, vol. 20, no. 6, pp. 1667–1673, 2019.
View at: Publisher Site | Google Scholar
S. A. Shah, G. H. Yoon, S. S. Chung et al., “Novel osmotin inhibits SREBP2 via the AdipoR1/AMPK/SIRT1 pathway to improve Alzheimer's disease neuropathological deficits,” Molecular Psychiatry, vol. 22, no. 3, pp. 407–416, 2017.
View at: Publisher Site | Google Scholar
W. Farris, S. Mansourian, Y. Chang et al., “Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 4162–4167, 2003.
View at: Publisher Site | Google Scholar
G. R. Tundo, D. Sbardella, C. Ciaccio et al., “Multiple functions of insulin-degrading enzyme: a metabolic crosslight?” Critical Reviews in Biochemistry and Molecular Biology, vol. 52, no. 5, pp. 554–582, 2017.
View at: Publisher Site | Google Scholar
I. V. Kurochkin, E. Guarnera, and I. N. Berezovsky, “Insulin-Degrading Enzyme in the Fight against Alzheimer’s Disease,” Trends in Pharmacological Sciences, vol. 39, no. 1, pp. 49–58, 2018.
View at: Publisher Site | Google Scholar
A. Stargardt, J. Gillis, W. Kamphuis et al., “Reduced amyloid-β degradation in early Alzheimer's disease but not in the APPswePS1dE9 and 3xTg-AD mouse models,” Aging Cell, vol. 12, no. 3, pp. 499–507, 2013.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2020 Xin-Yi Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

1867

Downloads

1506

Citations

Oxidative Medicine and Cellular Longevity

Pharmaceutical and Pharmacological Aspects of Modulation of Oxidative Stress 2020

Metformin Ameliorates Aβ Pathology by Insulin-Degrading Enzyme in a Transgenic Mouse Model of Alzheimer’s Disease

Abstract

1. Introduction

2. Material and Methods

2.1. Materials

2.2. Animals and Treatments

2.3. Morris Water Maze Test

2.4. Y-Maze Test

2.5. 18F-FDG PET Imaging

2.6. ELISA

2.7. ThT Staining

2.8. Measurement of SOD and MDA

2.9. qPCR

2.10. Western Blotting

2.11. Statistical Analysis

3. Results

3.1. Metformin Ameliorates Learning and Memory Dysfunctions in APP/PS1 Mice

3.2. Metformin Improves Brain Function in APP/PS1 Mice

3.3. Metformin Reduces Oxidative Stress and Inflammation in the Brain of APP/PS1 Mice

3.4. Metformin Reduces Aβ Accumulation in the Brain of APP/PS1 Mice

3.5. Metformin Activates AMPK and Increases IDE in the Brain of APP/PS1 Mice

4. Discussion

Data Availability

Conflicts of Interest

Authors’ Contributions

Acknowledgments

References

Copyright

2.5. ¹⁸F-FDG PET Imaging